NGMDF (NuGen Medical Devices) YoY EBITDA Growth: -128.57% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NuGen Medical Devices YoY EBITDA Growth?

NuGen Medical Devices NGMDF YoY EBITDA Growth is -128.57% as of Mar. 2026. The stock has 7 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. NuGen Medical Devices's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was -128.57%.

NuGen Medical Devices's EBITDA per Share for the three months ended in Mar. 2026 was $-0.00.

NuGen Medical Devices YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for NuGen Medical Devices's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NuGen Medical Devices YoY EBITDA Growth Chart

NuGen Medical Devices Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial -152.17 44.83 -3.13 69.70 -30.00

NuGen Medical Devices Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 240.00 0.00 62.50 -425.00 -128.57

NuGen Medical Devices YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

NuGen Medical Devices's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.013--0.01)/ | -0.01 |
=-30.00 %

NuGen Medical Devices's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.002-0.007)/ | 0.007 |
=-128.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -128.57% mean?
NuGen Medical Devices (NGMDF) has a YoY EBITDA Growth of -128.57% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for NuGen Medical Devices and its competitors.
Is NuGen Medical Devices' YoY EBITDA Growth too high?
NuGen Medical Devices' current YoY EBITDA Growth is -128.57%.
How does NuGen Medical Devices' YoY EBITDA Growth compare to ABT and SYK?
NuGen Medical Devices' YoY EBITDA Growth of -128.57% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for NuGen Medical Devices and its competitors. NuGen Medical Devices's current YoY EBITDA Growth is -128.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NuGen Medical Devices stock overvalued right now?
Based on GuruFocus' analysis, NuGen Medical Devices (NGMDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading 21.8% below its estimated fair value. The current YoY EBITDA Growth is -128.57%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For NuGen Medical Devices (NGMDF), the current YoY EBITDA Growth is -128.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NuGen Medical Devices Business Description

Other Exchanges 79O:GermanyNGMD:Canada
Address 18 King Street East, Suite 1400, Toronto, ON, CAN, M5C 1C4
NuGen Medical Devices Inc is a medical device manufacturing company specializing in the field of needleless injections and related technologies. The reportable segment of the company is the manufacturing of needle injector devices. Geographically, the company generates revenue from Europe, followed by Asia, and other.